Answers are grounded in this paper and cite their sources.
Evidence concerning growth hormone (GH) treatment initiated during infancy in Silver-Russell syndrome (SRS) remains limited. We describe a boy born small for gestational age with persistent feeding difficulties, growth restriction, and limb asymmetry. Methylation-specific multiplex ligation-dependent probe amplification identified 11p15.5 imprinting control region 1 hypomethylation at approximately 5 months. Weekly PEGylated recombinant human GH was initiated at 6 months because of molecularly confirmed SRS and marked growth restriction with feeding difficulties despite nutritional support; GH deficiency was not established. The target dose was 0.2 mg/kg/week, with recorded doses increasing from 1.0 to 2.5 mg/week. Treatment was interrupted for approximately 1 month during pneumonia. From 6 to 55 months, length/height increased from 62.1 to 103.5 cm and weight from 5.3 to 14.3 kg. World Health Organization length/height-for-age standard deviation score (SDS) increased from −2.58 to −0.84, a change of +1.75 SDS. Nutritional support included high-calorie formula until approximately 18 months. Available glucose and glycated hemoglobin results showed no apparent deterioration, but unavailable insulin-like growth factor 1 (IGF-1) SDS and absent latest biochemistry limit safety assessment. Follow-up blood samples were obtained before the scheduled weekly dose. At 56 months, caregiver-completed Ages and Stages Questionnaires, Third Edition screening yielded domain scores of 50–60/60, with residual motor concerns. This case describes an individualized course with approximately 49 months of growth follow-up; concurrent nutritional intervention and the absence of a comparator preclude attributing growth changes solely to GH or establishing the safety of infant initiation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: